Richard L. Love, Executive Chairman of the Board
Richard L. Love is a senior executive with 29 years of management experience in the bioscience industry. Mr. Love was a founder of two biopharmaceutical businesses, Triton Biosciences Inc. and ILEX Oncology Inc. and served as CEO for both companies for periods of 8 years each. At Triton and ILEX, Dick led teams that were responsible for the clinical development of multiple important therapeutic products, four of which remain in use: Betaseron® for treatment of patients with multiple sclerosis; Fludara® and CAMPATH®, both for patients with chronic lymphocytic leukemia; and ClolarTM for treatment of patients with acute lymphocytic leukemia. Triton was sold to Schering AG for proceeds in excess of $500 million (including earn-out) and ILEX was sold to Genzyme Corp for $1.04 billion. Mr. Love has also served in senior executive positions at three non-profit research institutions, the Cancer Therapy and Research Center, The San Antonio Technology Accelerator Initiative and the Translational Genomics Research Institute (TGen). Mr. Love is a managing partner in the Translational Accelerator Venture Fund (TRAC) and currently serves as a director of Parexel International (NASDAQ: PRXL); Cell Therapeutics Inc (NASDAQ: CTIC), Applied MicroArrays Inc., MedTrust OnLine LLC, and SalutarisMD. Mr. Love received an M.S. and B.S. in chemical engineering from Virginia Polytechnic Institute.
Barry J. Maurer, MD PhD, Chief Medical Officer and Acting Chief Executive Officer
Dr. Maurer is an outstanding bench-to-the-bedside physician-scientist, who is the Program Leader, Developmental Therapeutics Program, Texas Tech University Health Science Center School of Medicine (TTUHSC SOM) Cancer Center. His seminal discovery that fenretinide kills cancer cells but not normal cells by generating toxic waxes, known as ceramides, in cancer cells set the stage for a number of current and future oncology clinical trials. Dr. Maurer sponsors Investigational New Drug applications (IND) with the Food & Drug Administration, and chairs two active clinical trials of fenretinide in the national New Approaches to Neuroblastoma Therapy (NANT) consortium. He is also an active laboratory investigator funded by the National Cancer Institute (NCI) and serves on the NCI Developmental Therapeutics grant study section.
C Patrick Reynolds, MD PhD, Chief Scientific Officer
Dr. Reynolds, the Cancer Center Director and Associate Dean for Research TTUHSC SOM, is an internationally-recognized expert in development of novel drugs to treat cancer. His laboratory and clinical research led to use of a drug derived from vitamin A (13-cis-retinoic acid) to treat the childhood cancer neuroblastoma, a therapy that is now part of the world-wide standard of care. He is active in laboratory drug development research and also in the design and conduct of phase I, II, and III oncology clinical trials in both pediatric and adult oncology. Dr. Reynolds holds active grant support in cancer research from the National Cancer Institute, Department of Defense, the Children's Oncology Group, and he sponsors Investigational New Drug applications (IND) with the Food & Drug Administration. He serves on national advisory panels for the National Cancer Institute, the Food & Drug Administration, the Children's Oncology Group, and the National Institute of Child Health and Development. He has published more than 100 scientific papers on cancer drug development.